Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingShares Repurchased
Ratios

Pharma-Bio Serv (PBSV) EBIAT (2016 - 2026)

Pharma-Bio Serv filings provide 17 years of EBIAT readings, the most recent being -$94535.0 for Q1 2026.

  • On a quarterly basis, EBIAT fell 1207.49% to -$94535.0 in Q1 2026 year-over-year; TTM through Jan 2026 was -$102807.0, a 68.92% increase, with the full-year FY2025 number at -$100463.0, up 87.08% from a year prior.
  • EBIAT hit -$94535.0 in Q1 2026 for Pharma-Bio Serv, down from $403927.0 in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $460466.0 in Q3 2023 to a low of -$381782.0 in Q3 2024.
  • Median EBIAT over the past 5 years was $240027.0 (2022), compared with a mean of $93686.1.
  • Biggest five-year swings in EBIAT: soared 854.73% in 2024 and later tumbled 1207.49% in 2026.
  • Pharma-Bio Serv's EBIAT stood at $341640.0 in 2022, then plummeted by 113.8% to -$47148.0 in 2023, then soared by 854.73% to $355838.0 in 2024, then rose by 13.51% to $403927.0 in 2025, then tumbled by 123.4% to -$94535.0 in 2026.
  • The last three reported values for EBIAT were -$94535.0 (Q1 2026), $403927.0 (Q4 2025), and -$313877.0 (Q3 2025) per Business Quant data.